NASDAQ:PRLD

Prelude Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy PRLD

*Your capital is at risk

$3.66

+0.160 (+4.57%)

At Close: Jun 03, 2026

Prelude Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.98. In total, the insiders bought 17.18M and sold 1.44M PRLD shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.98
● Buy	17.18M shares
● Sell	1.44M shares
90% Buy Activity Negligible or No Correlation
Buy Signal High Confidence Apr 21, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 99.98. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (90% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
May 01, 2026 Buy	Employee Stock Option (right to buy) A-Award	Morris Charles Q Chief Medical Officer	Officer	450 000 Value: $2.12M
Apr 27, 2026 Buy	Pre-Funded Warrants (Right to Buy) J-Other	Ra Capital Management, L.p. 10 Percent Owner	10% Owner	1 407 000 Value: $141
Apr 27, 2026 Sell	Common Stock J-Other	Ra Capital Management, L.p. 10 Percent Owner	10% Owner	1 407 000 Value: $141
Apr 21, 2026 Buy	Common Stock	Ra Capital Management, L.p. 10 Percent Owner	10% Owner	0 Value: $0
Apr 21, 2026 Buy	Common Stock P-Purchase	Orbimed Advisors Llc	Director	1 126 126 Value: $5.00M
Apr 21, 2026 Buy	Common Stock P-Purchase	Orbimed Advisors Llc	Director	1 689 189 Value: $7.50M
Apr 21, 2026 Buy	Common Stock P-Purchase	Bonita David P	Director	1 126 126 Value: $5.00M
Apr 21, 2026 Buy	Common Stock P-Purchase	Bonita David P	Director	1 689 189 Value: $7.50M
Apr 21, 2026 Buy	Warrants to purchase Common Stock P-Purchase	Baker Bros. Advisors Lp	Director	2 137 651 Value: $214
Apr 21, 2026 Buy	Warrants to purchase Common Stock P-Purchase	Baker Bros. Advisors Lp	Director	114 601 Value: $11
Apr 15, 2026 Buy	Common Stock J-Other	Morris Charles Q Insider	Other	0 Value: $0
Mar 05, 2026 Buy	Common Stock	Brusky Sean P. Chief Business Officer	Officer	0 Value: $0
Mar 05, 2026 Buy	Employee Stock Option (Right to Buy)	Brusky Sean P. Chief Business Officer	Officer	275 000 Value: $858.0K
Feb 04, 2026 Buy	Employee Stock Option (right to buy) A-Award	Lim Bryant David Clo, CFO, Corp Sec.	C-Suite Officer	275 000 Value: $632.5K
Feb 04, 2026 Buy	Employee Stock Option (right to buy) A-Award	Combs Andrew Chief Chemistry Officer	Officer	230 000 Value: $529.0K
Feb 04, 2026 Buy	Employee Stock Option (right to buy) A-Award	Scherle Peggy Chief Scientific Officer	Officer	230 000 Value: $529.0K
Feb 04, 2026 Buy	Employee Stock Option (right to buy) A-Award	Vaddi Krishna CEO	CEO / President	837 000 Value: $1.93M
Nov 05, 2025 Buy	Director Stock Option (Right to Buy) A-Award	Sandor Victor Director	Director	121 285 Value: $168.6K
Oct 17, 2025 Buy	Common Stock J-Other	Dorton Katina Insider	Other	0 Value: $0
Oct 04, 2025 Buy	Common Stock M-Exempt	Huang Jane President, Cmo	CEO / President	9 375 Value: $34.3K
Oct 04, 2025 Sell	Common Stock F-InKind	Huang Jane President, Cmo	CEO / President	3 355 Value: $5K
Oct 04, 2025 Buy	Restricted Stock Unit M-Exempt	Huang Jane President, Cmo	CEO / President	9 375 Value: $34.3K
Oct 04, 2025 Buy	Restricted Stock Unit M-Exempt	Huang Jane President, Cmo	CEO / President	9 375 Value: $34.3K
Oct 04, 2025 Sell	Common Stock F-InKind	Huang Jane President, Cmo	CEO / President	3 355 Value: $5K
Oct 04, 2025 Buy	Common Stock M-Exempt	Huang Jane President, Cmo	CEO / President	9 375 Value: $34.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PRELUDE THERAPEUTICS INCORPORATED

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selecti...

Read Full Profile Here